News Release

Implementing post-genomic personalized medicine: The rise of glycan biomarkers

Peer-Reviewed Publication

Mary Ann Liebert, Inc./Genetic Engineering News

OMICS: A Journal of Integrative Biology

image: The only peer-reviewed journal covering all trans-disciplinary OMICs-related areas, including data standards and sharing; applications for personalized medicine and public health practice; and social, legal, and ethics analysis. view more 

Credit: Mary Ann Liebert, Inc., publishers

New Rochelle, NY, January 13, 2020--An in-depth look at the science of glycobiology and glycan diagnostics, and their promise in personalized medicine in the current post-genomic era are featured in a special issue of OMICS: A Journal of Integrative Biology, the peer-reviewed interdisciplinary journal published by Mary Ann Liebert, Inc., publishers. Click here to read the special issue on Glycomics and Personalized Glycomedicine free on the OMICS: A Journal of Integrative Biology website until February 15, 2020.

This special issue was co-edited by Wei Wang, MD, PhD, Edith Cowan University (Joondalup, Australia) and Capital Medical University (Beijing, China), and Vural Özdemir, MD, PhD, Editor-in-Chief of OMICS: A Journal of Integrative Biology. Dr. Wang and a team of researchers from Australia, China, and Croatia contributed an article entitled "Type 2 Diabetes Mellitus is Associated with the Immunoglobulin G N-Glycome through Putative Proinflammatory Mechanisms in an Australian Population.") The team analyzed the N-glycan patterns of immunoglobulin G (IgG) in individuals with type 2 diabetes (T2D) and found novel associations between the IgG N-glycome, T2D, and clinical risk factors related to proinflammatory mechanisms. These IgG N-glycomic alterations offer promise as future biomarkers for T2D diagnosis or monitoring of progression to cardiovascular disease or renal failure.

A review article by Tanja Kunej, PhD University of Ljubljana (Domzale, Slovenia) is entitled "Rise of Systems Glycobiology and Personalized Glycomedicine: Why and How to Integrate Glycomics with Multiomics Science?" Dr. Kunej proposes that for glycomics to make a greater, systems-scale contribution to biology and medicine, it needs to transition from a single omics science to multiomics technology platforms. The article presents examples of glycomics in association with other omics fields, including genomics, transcriptomics, proteomics, metabolomics, and epigenomics, and discusses current knowledge gaps and suggests future research directions.

Vural Özdemir, MD, PhD, Editor-in-Chief of OMICS: A Journal of Integrative Biology states: "Carbohydrates and glycans matter for personalized medicine. This OMICS special issue on glycomics and personalized glycomedicine signals the rise of glyco-theranostics as a new specialty in diagnostic medicine and systems science. It connects the dots between some of the most critical issues in biomarkers, post-genomic personalized medicine, and emerging technology governance to move systems science into clinical practice. Any reader interested in diagnostics in health care should benefit from reading the new OMICS issue curated with a systems approach to glycobiology and personalized/precision medicine."

###

About the Journal

OMICS: A Journal of Integrative Biology is an authoritative and highly innovative peer-reviewed interdisciplinary journal published monthly online, addressing the latest advances at the intersection of postgenomics medicine, biotechnology and global society, including the integration of multi-omics knowledge, data analyses and modeling, and applications of high-throughput approaches to study complex biological and societal problems. Public policy, governance and societal aspects of the large-scale biology and 21st century data-enabled sciences are also peer-reviewed. Complete tables of content and a sample issue may be viewed on the OMICS: A Journal of Integrative Biology website.

About the Publisher

Mary Ann Liebert, Inc., publishers is a privately held, fully integrated media company known for establishing authoritative peer-reviewed journals in many areas of science and biomedical research, including Journal of Computational Biology, ASSAY and Drug Development Technologies, and Zebrafish. Its biotechnology trade magazine, GEN (Genetic Engineering & Biotechnology News), was the first in its field and is today the industry's most widely read publication worldwide. A complete list of the firm's 80 journals, books, and newsmagazines is available on the Mary Ann Liebert, Inc., publishers website.


Disclaimer: AAAS and EurekAlert! are not responsible for the accuracy of news releases posted to EurekAlert! by contributing institutions or for the use of any information through the EurekAlert system.